Central nervous system sarcoma
diseaseOn this page
Also known as CNS sarcomasarcoma of central nervous systemsarcoma of CNSsarcoma of the central nervous systemsarcoma of the CNS
Summary
Central nervous system sarcoma (MONDO:0002217) is a cancer (an umbrella term covering 12 Mondo subtypes) and 4 clinical trials. A subtype of central nervous system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 12 Mondo subtypes
- Clinical trials: 4
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | central nervous system sarcoma |
| Mondo ID | MONDO:0002217 |
| DOID | DOID:2133 |
| NCIT | C5153 |
| UMLS | C1332892 |
| MedGen | 272444 |
| GARD | 0023088 |
| Anatomy (UBERON) | UBERON:0001017 |
| Is cancer (heuristic) | yes |
Also known as: central nervous system sarcoma · CNS sarcoma · sarcoma of central nervous system · sarcoma of CNS · sarcoma of the central nervous system · sarcoma of the CNS
Disease family
This is a subtype of central nervous system cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › central nervous system sarcoma
Related subtypes (19): central nervous system primitive neuroectodermal neoplasm, brain cancer, primary central nervous system lymphoma, central nervous system germinoma, central nervous system melanocytic neoplasm, central nervous system endodermal sinus tumor, spinal cord cancer, malignant carotid body paraganglioma, malignant adrenal gland pheochromocytoma, malignant jugulotympanic paraganglioma, pheochromocytoma/paraganglioma syndrome 2, pheochromocytoma/paraganglioma syndrome 5, central nervous system Ewing sarcoma/peripheral primitive neuroectodermal tumor, choriocarcinoma of the central nervous system, mixed germ cell tumor of central nervous system, embryonal carcinoma of the central nervous system, malignant tumor of meninges, malignant central nervous system mesenchymal, non-meningothelial neoplasm, malignant glioma
Subtypes (12): spinal cord sarcoma, brain sarcoma, central nervous system rhabdomyosarcoma, central nervous system angiosarcoma, central nervous system leiomyosarcoma, central nervous system fibrosarcoma, meningeal sarcoma, intracranial extraskeletal myxoid chondrosarcoma, central nervous system extraskeletal osteosarcoma, malignant peripheral nerve sheath tumor, atypical teratoid rhabdoid tumor, isolated melanotic schwannoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 2 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03641326 | PHASE2 | TERMINATED | Sunitinib in Sarcomas of the Central Nervous System |
| NCT03990597 | PHASE1 | WITHDRAWN | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord |
| NCT05697874 | Not specified | RECRUITING | International Rare Brain Tumor Registry |
| NCT03251989 | Not specified | COMPLETED | Rare CNS Tumors Outcomes &Risk |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CHEMBL275117 | 0 | 1 |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.